What is AIRFAST 5mg
AIRFAST 5 mg is the brand name for chewable tablets containing montelukast sodium 5 mg, a selective leukotriene-receptor antagonist (LTRA) used in the prophylaxis and long-term control of asthma and to relieve seasonal or perennial allergic rhinitis. By blocking the cysteinyl-leukotriene receptor 1 (CysLT1) in the airway and nasal mucosa, montelukast prevents bronchoconstriction, mucus hyper-secretion, and airway inflammation triggered by allergens, irritants, cold air, or exercise.
- Therapeutic class: Anti-asthmatic, Anti-allergic (LTRA).
- Indications:
- Maintenance treatment of persistent asthma (mild, moderate, or severe) in adults and children ≥ 6 months.
- Prevention of exercise-induced bronchoconstriction (EIB) in patients ≥ 6 years.
- Symptomatic relief of seasonal and perennial allergic rhinitis.
- Pharmaceutical form: Chewable tablet, strawberry-flavored, scored; lactose-free and gluten-free.
- Packaging: Blister pack 10 tablets × 3 (total 30) in a moisture-resistant carton.
- Regulatory status: Prescription-only medicine (Rx).
- Key benefits: Once-daily dosing, rapid onset within 2 h, steroid-sparing effect in asthma, no sedation, safe in aspirin-sensitive asthma.
- Limitations: Not indicated for acute asthma attacks; slower onset than short-acting β2-agonists for EIB; neuropsychiatric vigilance required.
How to use AIRFAST 5mg
Correct administration optimizes therapeutic benefit and minimizes adverse events.
- Dose & timing: One 5 mg chewable tablet once daily in the evening, taken at least 2 h before physical activity when used for EIB-prophylaxis. Evening dosing aligns with the circadian rise in leukotrienes.
- Administration method: Chew thoroughly before swallowing; may be taken with or without food. Follow with a sip of water.
- Missed dose: If < 12 h late, take as soon as remembered; if > 12 h, skip and resume usual schedule—do not double doses.
- Asthma action plan: Continue inhaled corticosteroid (ICS) or controller therapy; do not substitute AIRFAST abruptly for ICS. Keep rescue inhaler (SABA) accessible for acute bronchospasm.
- Pediatric guidance: For children 6–14 years, the 5 mg chewable form is preferred; ensure supervision to prevent choking and verify complete chewing.
- Peri-operative use: Continue therapy; no specific withholding period required.
- Monitoring: Review control every 4–8 weeks; assess peak flow, symptom-free nights, reliever use, and allergen exposure.
- Lifestyle advice: Avoid smoking; implement allergen avoidance strategies; maintain vaccination schedule (influenza, pneumococcal).
Mode of Action AIRFAST 5mg
Montelukast selectively inhibits the binding of cysteinyl-leukotrienes (LTC4, LTD4, and LTE4) to the CysLT1 receptor located on bronchial smooth muscle, eosinophils, macrophages, and endothelial cells.
- Leukotriene blockade: Prevents leukotriene-induced bronchoconstriction, mucosal edema, vascular permeability, and eosinophil recruitment.
- Anti-inflammatory profile: Reduces airway eosinophilia, serum IgE, and pro-inflammatory cytokines (IL-4, IL-5).
- No β-adrenergic activity: Avoids tachyphylaxis associated with chronic β2-agonist use and suitable for patients intolerant to sympathomimetics.
- Pharmacokinetics:
- Oral bioavailability ≈ 64%; peak plasma in 2–3 h.
- Highly protein-bound (≥ 99%).
- Extensive hepatic CYP3A4 and CYP2C9 metabolism; inactive metabolites excreted in bile.
- Terminal half-life 2.7–5.5 h; effect persists ≥ 24 h, permitting once-daily dosing.
- Clinical implications: Improves FEV1, reduces nighttime awakenings, lowers rescue inhaler use, and prevents EIB within 2 h of dosing.
- Extrapulmonary benefits: Diminishes nasal congestion, rhinorrhoea, and sneezing in allergic rhinitis by acting on nasal mucosa leukotriene receptors.
- Steroid-sparing: May allow ICS dose reduction in well-controlled asthma, minimizing systemic corticosteroid exposure.
AIRFAST 5mg Interactions AIRFAST 5mg
Montelukast is primarily a substrate of hepatic CYP3A4 and CYP2C9; clinically relevant interactions are uncommon but vigilance is prudent.
- Enzyme inducers:
- Rifampicin, phenobarbital, phenytoin, carbamazepine increase CYP activity → ↓ montelukast plasma levels (30-60%) → possible loss of efficacy; consider dose monitoring or alternative agent.
- Enzyme inhibitors: Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir) have negligible effect on montelukast exposure; no adjustment required.
- Warfarin: Studies show no clinically important change in INR, but isolated reports of altered coagulation exist; monitor INR when initiating or discontinuing AIRFAST.
- Gemfibrozil: May double montelukast AUC via OATP inhibition; not clinically significant but observe for neuropsychiatric events.
- Biologics (omalizumab, mepolizumab): Concomitant use is safe and may be complementary in severe asthma.
- Food & herbal supplements: Grapefruit juice has minimal effect; St John’s wort (CYP3A4 inducer) may lower levels—avoid concurrent use.
- Alcohol & CNS depressants: No pharmacokinetic interaction, but additive neuropsychiatric adverse effects (insomnia, agitation) may occur; caution advised.
- Vaccines: No interference with immune response; continue routine immunisation.
Dosage of AIRFAST 5mg
Dosing must be individualized based on age, clinical response, and concomitant therapy.
- Standard dosage (6–14 years): 5 mg chewable tablet once daily in the evening.
- Adults & adolescents ≥ 15 years: 10 mg film-coated tablet once daily (use appropriate strength).
- Prophylaxis of EIB: 5 mg (children) or 10 mg (adults) taken ≥ 2 h before exercise; do not repeat within 24 h.
- Allergic rhinitis: Same dose as asthma; may be started or discontinued based on allergen season.
- Renal impairment: No dose adjustment—minimal renal clearance.
- Hepatic impairment: Mild-to-moderate: no adjustment; severe hepatic insufficiency: use with caution, limited data.
- Elderly (≥ 65 years): Pharmacokinetics comparable to younger adults; standard dose appropriate.
- Dose escalation: Doses > 10 mg daily show no additional benefit and increase adverse effects—do not exceed recommended maximum.
- Treatment duration: Continue long-term to maintain control; reassess need every 6–12 months.
Possible side effects of AIRFAST 5mg
Montelukast is generally well tolerated; most adverse reactions are mild and transient.
- Common (≥ 1%):
- Headache, abdominal pain, dyspepsia.
- Upper respiratory infection, cough, pharyngitis.
- Diarrhoea, nausea, vomiting.
- Uncommon (< 1%):
- Rash, eczema, pruritus.
- Asthenia, fatigue, pyrexia.
- Neuropsychiatric: Insomnia, agitation, anxiety, dream abnormalities, irritability; rare reports of hallucinations, depression, suicidal thinking—counsel caregivers and discontinue if severe.
- Hypersensitivity: Urticaria, angio-oedema, anaphylaxis (rare); stop immediately and treat per anaphylaxis protocol.
- Eosinophilic systemic features (Churg–Strauss syndrome): Occurs mainly during corticosteroid tapering; watch for fever, vasculitic rash, neuropathy.
- Hepatic: Elevations of ALT/AST, cholestatic hepatitis; monitor LFTs if symptoms (jaundice, right-upper-quadrant pain) appear.
- Others: Palpitations, bruising, arthralgia, myalgia, thrombocytopenia—very rare.
- Management: Most mild reactions resolve without therapy; severe events warrant discontinuation and specialist review.
AIRFAST 5mg Contraindications AIRFAST 5mg
- Known hypersensitivity to montelukast, any LTRA, or tablet excipients (mannitol, aspartame, red iron oxide).
- Phenylketonuria: Chewable tablets contain aspartame (source of phenylalanine) 0.842 mg per dose—avoid in patients with PKU.
- Acute asthma exacerbation: Not for reversal of status asthmaticus; use rapid-acting β2-agonist and systemic corticosteroid.
- Severe hepatic impairment (Child–Pugh C): Limited clinical data; avoid use.
- Previous neuropsychiatric reaction clearly linked to montelukast (e.g., suicidal ideation); rechallenge discouraged.
- Concomitant use of strong CYP3A4 inducers in patients whose asthma is unstable despite maximal therapy—therapeutic failure likely.
- Breast-feeding caution: Montelukast is excreted in breast milk in low concentrations; use only if benefits outweigh risks.
Storage of AIRFAST 5mg
- Temperature: Store below 30 °C (86 °F); brief excursions up to 40 °C permissible (< 48 h) without loss of potency.
- Humidity: Keep in original foil blisters until use; montelukast is hygroscopic and degrades with moisture.
- Light protection: Protect from direct sunlight; active ingredient is photosensitive at high intensities.
- Child safety: Child-resistant carton; keep out of sight and reach of children.
- Transport: Avoid freezing and excessive heat during shipment; use insulated packaging if ambient > 40 °C.
- Shelf life: 36 months from date of manufacture when stored as recommended; check expiry date printed on carton and blister.
- Disposal: Do not flush unused tablets; mix with undesirable substance (coffee grounds), place in sealed bag, and discard per local regulations or return to pharmacy take-back program.
AIRFAST 5mg features an exceptional active ingredient renowned for its potent effects, comprising Montelukast (as sodium). This powerful formulation provides a superior solution for addressing diverse health concerns. With 5mg/Tablet concentration and an easily manageable Tablets/Chewable, it remains a preferred option for countless individuals seeking effective treatment.
Introduction
All you need to know about AIRFAST 5mg .
Welcome to Dwaey, specifically on AIRFAST 5mg page.
This medicine contains an important and useful components, as it consists of Montelukast (as sodium).
AIRFAST 5mg is available in the market in concentration 5mg/Tablet and in the form of Tablets/Chewable.
TABUK PHARMACEUTICAL MANUFACTURING CO is the producer of AIRFAST 5mg and it is imported from SAUDI ARABIA,
The most popular alternatives of AIRFAST 5mg are listed downward .
-
Active Substance
-
Size
-
Indications
-
Type
-
Company
TABUK PHARMACEUTICAL MANUFACTURING CO
Frequently Asked Questions
AIRFAST 5mg should be stored according to the instructions provided by TABUK PHARMACEUTICAL MANUFACTURING CO.
In general, it is recommended to store AIRFAST 5mg in a cool, dry place, away from direct sunlight
and out of the reach of children.
The duration of treatment with AIRFAST 5mg may vary depending on the condition being treated
and the guidance of your healthcare provider. It is important to follow the prescribed treatment
plan and continue taking AIRFAST 5mg for the recommended duration, even if your symptoms improve.
If you have any concerns or questions about the duration of treatment, consult your healthcare provider.
It is important to check with your healthcare provider or read the medication label for specific
instructions regarding alcohol consumption while taking AIRFAST 5mg. Some medications, including
AIRFAST 5mg, may have interactions with alcohol that can reduce effectiveness, increase side
effects, or pose other risks to your health. It is best to follow the guidance provided by your
healthcare professional.
If you miss a dose of AIRFAST 5mg, take it as soon as you remember. However, if it is close
to the time for your next scheduled dose, skip the missed dose and continue with your regular dosing
schedule. Do not take a double dose to make up for a missed one unless advised by your healthcare provider.
No, do not stop taking AIRFAST 5mg without consulting your healthcare provider, even if your
symptoms improve. It is important to complete the full course of treatment as prescribed. Stopping
the medication prematurely may lead to a relapse or incomplete resolution of the condition. If you
have concerns about the duration of treatment, consult your healthcare provider for guidance.
It is important to consult your healthcare provider before taking AIRFAST 5mg if you are
pregnant or breastfeeding. They will be able to assess the potential risks and benefits based on your
specific situation. Please note that the safety and suitability of AIRFAST 5mg during pregnancy
or breastfeeding may depend on the active substance [Active Substance], concentration 5mg/Tablet,
and the specific recommendations of TABUK PHARMACEUTICAL MANUFACTURING CO.
The effects of AIRFAST 5mg on your ability to drive or operate machinery can vary depending on
the active substance [Active Substance], concentration 5mg/Tablet, and individual factors.
Some medications may cause drowsiness, dizziness, or other side effects that can impair your judgment
or coordination. It is important to read the medication label or consult your healthcare provider to
understand any potential effects on your ability to perform tasks that require alertness.
The instructions for taking AIRFAST 5mg with or without food may vary depending on the medication
and the recommendations of TABUK PHARMACEUTICAL MANUFACTURING CO. Some medications may be more effective when taken with
food to enhance absorption or reduce stomach irritation, while others may need to be taken on an empty
stomach for optimal absorption. Read the medication label or consult your healthcare provider for specific instructions.
The use of AIRFAST 5mg in children or elderly individuals may depend on various factors, including
the specific medication, type Tablets/Chewable, and the recommendations of TABUK PHARMACEUTICAL MANUFACTURING CO. Some
medications may have specific dosing instructions or precautions for these age groups. Consult your
healthcare provider or read the medication label for information regarding the safe and appropriate use
of AIRFAST 5mg in children or elderly individuals.
Dwaey
All medical information published on the Dwaey website aims to increase medical awareness and health education among users. However, it is not a substitute for professional medical advice. Always consult with a specialist doctor. We strongly advise against using any information or medicine found on the site without referring to your healthcare provider.
Related Products
0 Comments